株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

英国の製薬・バイオテクノロジー分野における建設市場の分析

Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis

発行 AMA Research 商品コード 251790
出版日 ページ情報 英文 98 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
英国の製薬・バイオテクノロジー分野における建設市場の分析 Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis
出版日: 2016年09月16日 ページ情報: 英文 98 Pages
概要

当レポートでは、英国のライフサイエンス部門で活動する建設会社とそのサプライチェーン、およびラボ・関連製品のサプライヤーに注目して調査し、製薬、医療技術、医療・産業用バイオテクノロジー部門の市場規模、主要企業および集中地域、英国における主な製造・R&D施設の概要、サイエンス・研究用の政府資源・投資資金の分析、製薬市場が直面している課題のレビューなどをまとめてお届けします。

第1章 イントロダクション

第2章 サマリー・将来予測

第3章 市場規模・概要

  • 市場定義・市場規模・市場額
    • 世界の製薬市場
    • 英国の製薬市場
    • 医療技術部門
    • 医療バイオテクノロジー部門
    • 産業バイオテクノロジー部門
    • 製薬部門
  • 製薬/バイオテクノロジーの集中地域
    • オックスフォードシャー
    • ロンドン、ケンブリッジ、スティーブニッジ
    • 製薬製造/R&Dの地理的ロケーション
  • 英国経済に対する製薬産業の価値
    • 製薬における英国の貿易
    • NHSへの医薬品の販売
  • 英国における製薬のR&D
    • サイエンスR&D用の政府資金
    • 製薬企業のR&D投資
    • R&Dパイプライン
  • 製薬産業の市場促進因子・主な課題
    • 英国におけるR&Dの将来

第4章 製薬・バイオテクノロジー部門における主要企業/大学

  • 概要
  • 製薬企業のランキング表
    • 世界
    • 英国
  • 企業プロファイル
    • Abbott Laboratories
    • AstraZeneca
      • GlaxoSmithKline (GSK)
    • Lilly
    • Merck & Co. Inc
    • Novartis
    • Pfizer
    • Roche
    • Sanofi-Aventis
    • Teva
  • その他の製薬/バイオテクノロジー企業
    • バイオテクノロジー:治療/診断
    • バイオテクノロジーR&D
    • 製薬
    • 英国サイエンスパーク

第5章 製薬・バイオテクノロジー分野における建設活動

  • 製薬分野における資本支出
  • 製薬における建設プロジェクトのパイプライン
  • 製薬産業における建設の課題
    • 建設コスト
    • 汚染/管理の問題

第6章 製薬&バイオテクノロジー分野における建設能力と供給

  • 概要
    • 特殊クリーンルームの建設、供給およびサービス
    • 建設コンサルタント&請負業者:製薬&バイオテクノロジー部門

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: Bld108

The 3rd edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis' addresses the scale of construction activity in the pharmaceutical and biotechnology industry alongside the key contractors operating in that sector. It also assesses the health of the pharmaceutical industry and whether prospective industry performance is likely to lead to greater levels of capital and construction investment.

image1

Key sections covered:

  • Market size and overview - value, market drivers and key issues, R&D and manufacturing activity.
  • Construction activity - in the pharmaceutical and biotechnology industries.
  • Main manufacturing and R&D facilities - the key centres of the South East, East of England, North West, North East and Scotland.
  • Construction capability - major companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects.
  • Funding and investment - analysis of Government resource and capital funding for science and research.


Key areas of insight include:

  • Analysis of the impact of Brexit on the UK pharmaceutical sector - there are significant issues for the industry including the regulation of medicines, EU clinical trials regulation, EU funding for research, access to R&D facilities, the single market, skills base.
  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Construction costs and issues in the design of pharmaceutical R&D and manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
  • Detailed analysis of pharmaceutical clusters and centres of excellence in the UK. Many of the UK's biotech firms are located in an area known as 'The Golden Triangle', with the centres of London, Cambridge, Oxford and Stevenage housing the UK's largest biomedical cluster in the UK.
  • Review of the main challenges facing the pharmaceutical sector including slowing R&D pipelines, dwindling healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls, the influence of the generic drugs market and increased pricing pressures.

Some of the companies mentioned in the report include:

ABB Group, AECOM, AMEC Foster Wheeler, Ardmac, Bassaire, BDP, Bilfinger SE, Cavendish Engineers, Clean Air Technologies, Clean Modules, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, ISG, Jacobs Engineering, John Sisk & Sons, Kier Group, Laing O'Rourke, M+W Group, Mach-Aire, Merit Merrell, Morgan Sindall, Nuvia, PM Group, Precision Cleanrooms, SDC, Sheppard Robson, Validair, Wilson Mason.

Key areas covered in the report include:

MARKET OVERVIEW

  • Market definition, size and value , overview of the global pharmaceutical market, overview of the UK pharmaceutical market : biopharmaceuticals; medical technology; digital health; genomics sector.
  • Location of UK biopharmaceutical manufacturing and R&D sites .
  • Pharmaceutical/biotechnology clusters and centres of excellence : Oxfordshire biocluster; London, Cambridge and Stevenage bioclusters.
  • Regional concentration of pharmaceutical manufacturing and R&D: Northwest; East, Southeast and London; Northeast; Scotland.
  • Future of pharmaceutical manufacturing operations in the UK.
  • Value of pharmaceutical industry to the UK economy: UK trade in pharmaceuticals, sales of pharmaceutical drugs to the NHS.
  • Pharmaceutical R&D in the UK: government funding for science R&D (resource & capital funding); pharmaceutical company investment in R&D; R&D pipeline.
  • Market drivers and key issues in the pharmaceutical industry: drug patent expirations; generic drugs market; university collaboration with the pharmaceutical industry; tax implications and government legislation; long-term implications of 'brexit' on the UK pharmaceutical industry.

CONSTRUCTION ACTIVITY

  • Construction output in the UK pharmaceutical and biotechnology sector , forecast through to 2020, prospects for development in construction within this end use sector.
  • Construction in the industrial sector, future prospects in construction output within the sector, key influencing factors, growth in factories and warehouses.
  • Capital expenditure in the UK pharmaceutical & biotechnology sectors: R&D capital and manufacturing capital.
  • Pharmaceutical construction/development pipeline - confirmed projects to 2020.
  • Construction issues in the pharmaceutical industry - construction costs; contamination control issues; clean rooms; containment laboratories; legislation/guidelines/standards for cleanroom construction.
  • UK science parks and university innovation campuses.
  • UK Enterprise Zones and Catapult Centres .

CONSTRUCTION CAPABILITY

  • Leading specialist supply companies to the pharmaceutical industry including: cleanroom design, construction and fit-out; clean and controlled air environments; clean air products; bio-containment and contamination control; validation and maintenance.
  • Major engineering construction companies involved in the pharmaceutical and biotechnology sectors including contractors, consultants and architects - capability and project experience.

LEADING PHARMACEUTICAL COMPANIES

  • Overview and Pharmaceutical Company League Tables (Global and UK).
  • Pharmaceutical company profiles : Abbvie; AstraZeneca; Boehringer Ingelheim; GSK; Johnson & Johnson; Merck; Novartis; Pfizer; Roche; Sanofi.
  • Other smaller pharmaceutical/biotechnology companies: biotechnology/therapeutics & diagnostics; biotechnology R&D; pharmaceutical.

SUMMARY OF REPORT CONTENTS

The UK is one of the largest pharmaceutical markets in the world, and the sector makes a greater contribution to the UK economy than any other industrial sector. Though there has been some scaling-back of R&D budgets in the UK in recent years, due to issues such as slowing R&D pipelines, dwindling R&D and healthcare budgets, rising costs, impending 'patent cliffs', increased regulatory controls and increased pricing pressures, pharmaceutical manufacturing investment activity in the UK has been slowly increasing over the last couple of years. Confidence has begun to return to the market and this looks set to continue into 2016-17, despite the ongoing threat of global economic uncertainty and the more recent threat of the UK's exit from the EU. The level of construction output in the pharmaceutical sector has also grown in recent years, with a focus of developments on high-value laboratories / cleanrooms.

Although the volume of work has increased, tender opportunities are becoming increasingly competitive resulting in tighter margins and, despite renewed activity, many UK pharmaceutical producers are not significantly increasing levels of capex. However, the Government has announced a forward pipeline of over £1.9bn worth of capital projects in the pharmaceutical and biotechnology sectors between now and 2020. In addition to these confirmed capital projects, a number of expansion plans have been announced by leading pharmaceutical companies, which should be of interest to construction companies and their supply chains operating in the pharmaceutical sector. In addition, a major trend in 2016 is the continued capital investment in science parks and university innovation campuses, with a focus on R&D, and enterprise zones.

In terms of construction costs, pharmaceutical R&D and manufacturing facilities are among the most energy intensive and expensive of buildings and are also highly regulated in terms of design and function. Current design and construction trends are moving away from 'bespoke' buildings to flexible and mobile laboratories and cleanrooms requiring less time to design and build and incorporating modern methods of construction. The demand for mobile or modular cleanrooms is increasing driven by industry cutbacks which have forced many pharmaceutical companies to rethink their business and manufacturing operations. Increasing specialisation within the pharmaceutical industry has brought about varied opportunities for construction engineers and contractors to design and develop R&D facilities, pharmaceutical production processes, and assembly of drug delivery devices/systems, construction and maintenance of highly specialised production facilities and associated service/support facilities.

So far, the larger pharmaceuticals companies appear to have been largely unscathed by the UK vote to leave the EU - with a significant proportion of the sales of the major pharmaceutical companies generated overseas and a weaker pound likely to result in a significant rise in profits. However, Brexit has the potential to create significant issues for the UK life sciences industry including the regulation of medicines, EU clinical trials regulations, EU funding for research and access to R&D facilities, access to the single market and R&D workforce and intellectual property. The industry is expected to continue to show modest growth over the next few years, reflecting the positive growth factors from the growing UK pharmaceutical industry, but constrained by the economic uncertainty created by the UK's vote to leave the EU.

Table of Contents

CONTENTS and LIST OF TABLES & CHARTS

1 INTRODUCTION

  • 1.1 INTRODUCTION
  • 1.2 SOURCES OF INFORMATION

2 SUMMARY AND MARKET PROSPECTS

  • 2.1 SUMMARY
  • 2.2 UK PHARMACEUTICALS SECTOR

3 ECONOMIC ENVIRONMENT

  • 3.1 GDP
  • 3.2 INFLATION & INTEREST RATES
  • 3.3 UNEMPLOYMENT
  • 3.4 HOUSEHOLD CONSUMPTION
  • 3.5 HOUSING & CONSTRUCTION
  • 3.6 STERLING
  • 3.7 POPULATION PROFILE
  • 3.8 CONCLUSIONS

4 CONSTRUCTION ACTIVITY IN THE UK PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS

  • 4.1 CONSTRUCTION INDUSTRY
    • 4.1.1 Overall Construction Industry
    • 4.1.2 Non-Domestic Construction
  • 4.2 DEFINITION - PHARMACEUTICALS AND BIOTECHNOLOGY
  • 4.3 MARKET SIZE
    • 4.3.1 Current Situation
    • 4.3.2 Market Prospects
    • 4.3.3 Construction Pipeline
  • 4.4 CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR
  • 4.5 SCIENCE PARKS / UNIVERSITY INNOVATION CAMPUSES
  • 4.6 ENTERPRISE ZONES
  • 4.7 CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY
    • 4.7.1 Construction Costs
    • 4.7.2 Contamination Control Issues

5 CONSTRUCTION CAPABILITY AND SUPPLY CHAIN

  • 5.1 OVERVIEW OF THE SUPPLY CHAIN
  • 5.2 CONSTRUCTION CONSULTANTS AND CONTRACTORS
  • 5.3 SPECIALIST CLEANROOM CONSTRUCTION, SUPPLY AND SERVICES

6 PHARMACEUTICAL INDUSTRY MARKET SIZE AND OVERVIEW

  • 6.1 MARKET DEFINITION, SIZE AND VALUE
    • 6.1.1 Global Pharmaceutical Market
    • 6.1.2 UK Pharmaceutical Market
    • 6.1.3 Biopharmaceutical Sector
    • 6.1.4 Medical Technology Sector
    • 6.1.5 Digital Health Sector
    • 6.1.6 Genomics Sector
    • 6.1.7 Location of Biopharmaceutical Manufacturing Sites
  • 6.2 PHARMACEUTICAL / BIOTECHNOLOGY CLUSTERS
    • 6.2.1 Oxfordshire BioCluster
    • 6.2.2 London, Cambridge and Stevenage BioClusters
    • 6.2.3 Regional Concentration of Pharmaceutical Manufacturing/R&D
    • 6.2.4 Future of Pharmaceutical Manufacturing Operations in the UK
  • 6.3 VALUE OF PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY
    • 6.3.1 UK Trade in Pharmaceuticals
  • 6.4 SALES OF PHARMACEUTICAL DRUGS TO THE NHS
  • 6.5 PHARMACEUTICAL R&D IN THE UK
    • 6.5.1 Government Funding for Science R&D
    • 6.5.2 Pharmaceutical Company Investment in R&D
    • 6.5.3 R&D Pipeline
  • 6.6 MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY
    • 6.6.1 Key General Issues Facing the Pharmaceutical Sector
    • 6.6.2 Future of the UK Pharmaceutical Sector

7 LEADING COMPANIES IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTORS

  • 7.1 OVERVIEW
  • 7.2 PHARMACEUTICAL COMPANY LEAGUE TABLES
    • 7.2.1 Global
    • 7.2.2 UK
  • 7.3 COMPANY PROFILES
    • 7.3.1 AbbVie
    • 7.3.2 AstraZeneca
    • 7.3.3 Boehringer Ingelheim
    • 7.3.4 GSK
    • 7.3.5 Johnson & Johnson
    • 7.3.6 Merck
    • 7.3.7 Novartis
    • 7.3.8 Pfizer
    • 7.3.9 Roche
    • 7.3.10 Sanofi
  • 7.4 OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES
    • 7.4.1 Biotechnology - Therapeutics/Diagnostics
    • 7.4.2 Biotechnology R&D
    • 7.4.3 Pharmaceutical

TABLES AND CHARTS

  • CHART 1 ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020
  • TABLE 2 GDP DATA - 2013-2016 - KEY CONSTITUENT ELEMENTS
  • CHART 3 INTEREST RATES AND INFLATION (CPI) FROM 2000-2020
  • CHART 4 PDI & SAVINGS RATIO AT CURRENT PRICES 2000-2020
  • TABLE 5 EXCHANGE RATE FLUCTUATIONS 2012-2018 - STERLING TO THE DOLLAR, AND THE EURO, SPOT RATES
  • CHART 6 CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2011 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES)
  • CHART 7 CONSTRUCTION OUTPUT (GB) NEW WORK AND RMI ANALYSIS 2015 TO 2020 BY VALUE (£ BILLION AT CURRENT PRICES)
  • CHART 8 NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) NEW WORK & RMI - CURRENT PRICES (£BN) 2011 -2020
  • CHART 9 NON RESIDENTIAL CONSTRUCTION OUTPUT (GREAT BRITAIN) BY SECTOR CURRENT PRICES (£BN) 2014 -2020
  • CHART 10 ESTIMATED VALUE OF CONSTRUCTION OUTPUT IN THE PHARMACEUTICALS AND BIOTECH INDUSTRY BY VALUE (£M AT CURRENT PRICES) 2011-2020
  • TABLE 11 UK SCIENCE AND RESEARCH PROJECTS - FORWARD CONSTRUCTION PIPELINE
  • CHART 12 UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - R&D AND MANUFACTURING OPERATIONS (£M) 2009 - 2014
  • TABLE 13 UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS AND KEY PARTNERS
  • TABLE 14 AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEANROOMS (BASED ON ISO 14644-1)
  • CHART 15 GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN) - 2011 - 2020
  • CHART 16 SIZE OF THE UK LIFE SCIENCES SECTOR BY TURNOVER AND NO. COMPANIES 2015 (BIOPHARMACEUTICALS AND MEDICAL TECHNOLOGY) (BY % AND VALUE £BN)
  • TABLE 17 BIOPHARMACEUTICAL / MEDICAL TECHNOLOGY SECTORS - MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN THE UK - MANUFACTURING, R&D, AND PACKAGING & LOGISTICS
  • CHART 18 UK PHARMACEUTICAL SECTOR - DISTRIBUTION OF UK MANUFACTURING AND R&D SITES
  • CHART 19 PHARMACEUTICAL TRADE IN THE UK - 2010- 2015 BY VALUE (£M)
  • TABLE 20 GOVERNMENT RESOURCE FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M)
  • TABLE 21 GOVERNMENT CAPITAL FUNDING FOR SCIENCE AND RESEARCH 2016-2020 BY FUNDING PROGRAMME (£M)
  • TABLE 22 TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL R&D SPEND 2015 (£BN AND BY % OF TURNOVER)
  • TABLE 23 TOP 20 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2015 AND 2016
  • TABLE 24 TOP 20 GLOBAL PHARMACEUTICAL COMPANIES BY MARKET SHARE (%) 2015
  • TABLE 25 TOP 10 PHARMACEUTICAL COMPANIES MARKET SHARE (%) 2015
  • TABLE 26 ABBVIE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 27 ASTRAZENECA - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 28 BOEHRINGER INGELHEIM - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS
  • TABLE 29 GSK- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS
  • TABLE 30 JOHNSON & JOHNSON - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 31 MERCK - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 32 NOVARTIS - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 33 PFIZER- KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 34 ROCHE - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
  • TABLE 35 SANOFI - KEY OPERATING AND FINANCIAL SUMMARY DATA (TURNOVER, CAPEX, R&D, PRINCIPAL ACTIVITIES, KEY UK LOCATIONS)
Back to Top